ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0054 • ACR Convergence 2023

    RA Monocytes and Monocyte-Derived Macrophages Display Heightened Inflammatory Responses, Reduced Endocytic Capacity and Distinct TET Expression Compared to PsA Monocytes

    Success Amaechi1, Megan Hanlon2, Alyssa Gilmore2, Dumitru Anton2, Mary Canavan3, Sonia Sundanum4, Carl Orr5, Douglas Veale6, Viviana Marzaioli7 and Ursula Fearon8, 1Trinity College Dublin, Mullingar, Ireland, 2Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 3Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, School of Biochemistry & Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, 4EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 5Saint Vincent's University Hospital, Dublin, Ireland, 6St.Vincent's University Hosp, Dublin, Ireland, 7Trinity College Dublin and University College Dublin, Dublin, Ireland, 8Trinity College Dublin, Dublin, Ireland

    Background/Purpose: RA and PsA share various pathogenic features, while also displaying significant differences at the clinical, cellular and molecular levels. In this study, we investigate…
  • Abstract Number: 0155 • ACR Convergence 2023

    Cost Analysis of Subcutaneous Methotrexate Compared to Oral Methotrexate Treatment for Rheumatoid Arthritis

    Aniket Kawatkar, David Yi, Erika Estrada and Cecilia Portugal, Kaiser Permanente Southern California, Pasadena, CA

    Background/Purpose: Rheumatoid Arthritis (RA)patients who switch from oral to subcutaneous methotrexate (MTX) may experience better response to treatment due to increased bioavailability, enhanced tolerability, increased…
  • Abstract Number: 0321 • ACR Convergence 2023

    Use of Proton Pump Inhibitors and Risk of Hip/knee Joint Replacement Among Patients with Osteoarthritis and Rheumatoid Arthritis

    Koushik Sangaraju1, Radu Grovu2, Michael Kwark2, Elizabeth Cohen2, Amira Hassan3 and Anastasia Slobodnick2, 1Staten Island University Hospital - Northwell Health, Staten Island, NY, 2Northwell Health, Staten Island, NY, 3Northwell Health, Brooklyn, NY

    Background/Purpose: Osteoarthritis and rheumatoid arthritis cause significant joint replacement morbidity. Proton pump inhibitors (PPIs) may contribute to chronic inflammation and joint degeneration due to side…
  • Abstract Number: 0391 • ACR Convergence 2023

    Biologic Use Regulates the Impact of Inflammation on Ischemic Cardiovascular Risk in Rheumatoid Arthritis

    George Karpouzas1, Sarah Ormseth2, Piet Van Riel3, Elena Myasoedova4, Miguel A Gonzalez-Gay5, Alfonso Corrales6, Solbritt Rantapää-Dahlqvist7, Petros Sfikakis8, Patrick Dessein9, Linda Tsang9, Carol Hitchon10, Hani El Gabalawi10, Virginia Pascual Ramos11, Irazú Contreras Yañez12, Iris Colunga13, Dionicio A. Galarza-Delgado13, José Ramón Azpiri-López13, Silvia Rolefstad14, Anne Grete Semb15, Durga P Misra16, Ellen Margrethe Hauge17 and GEORGE KITAS18, 1Harbor-UCLA Medical Center, Torrance, CA, 2The Lundquist Institute, Torrance, CA, 3Radboud University Medical Center, Drunen, Netherlands, 4Mayo Clinic, Rochester, MN, 5IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, 6Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, 7Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, 8National Kapodistrian University of Athens Medical School, Athens, Greece, 9University of Witwatersrand, Johannesburg, South Africa, 10University of Manitoba, Winnipeg, MB, Canada, 11Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 12Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 13Hospital Universitario UANL, Monterrey, Mexico, 14Diakonhjemmet Hospital, Oslo, Norway,, Oslo, Norway, 15Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, 16Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, 17Aarhus University Hospital, Aarhus, Denmark, 18The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom

    Background/Purpose: Chronic inflammation contributes to enhanced cardiovascular risk in rheumatoid arthritis (RA). Biologic disease modifying antirheumatic drugs (bDMARDs) control inflammation in many conventional synthetic DMARD…
  • Abstract Number: 0408 • ACR Convergence 2023

    The Role of Synovial Biopsy in Evaluating Rheumatoid Arthritis Acitivity in Patients: Findings from a Study of 30 Patients Treated with Adalimumab

    Rui Wu and YIlin Peng, the first affilated hospital of Nanchang University, Nanchang, China

    Background/Purpose: Rheumatoid arthritis(RA)is a chronic autoimmune disease that is characterized by inflammation and destrction of synovial jionts  which result in high disabilty. Treat-to-Target is critical…
  • Abstract Number: 0425 • ACR Convergence 2023

    Long-term Safety of Rituximab in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

    Ioasaf Karafotias, Joshua Rothwell, Maryam Adas, Bechman Katie, Mark Russell, Sam Norton and James Galloway, King's College London, London, United Kingdom

    Background/Purpose: Rituximab targets CD20-bearing B cells and is used to treat Rheumatoid Arthritis (RA). Common Variable Immune Deficiency (CVID) is a primary immune deficiency syndrome…
  • Abstract Number: 0441 • ACR Convergence 2023

    Outcomes in Patients with Rheumatoid Arthritis Initiating Therapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors

    Dimitrios Pappas1, Jacqueline O’Brien1, Lin Guo1, Ying Shan1, Joshua Baker2, Gregory Kricorian3, Scott Stryker4 and David Collier3, 1CorEvitas, LLC, Waltham, MA, 2University of Pennsylvania, Philadelphia, PA, 3Amgen, Inc., Thousand Oaks, CA, 4Amgen, Inc., San Francisco, CA

    Background/Purpose: Ongoing debate exists regarding the optimal sequence of tumor necrosis factor inhibitors and Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis (RA) as…
  • Abstract Number: 0458 • ACR Convergence 2023

    Drug Switching Due to Inefficacy in Rheumatoid Arthritis Patients Treated with Biological and Targeted Therapies. Daily Clinical Experience

    Maria Rodriguez Laguna1, Zulema Rosales-Rosado2, Cristina Vadillo-Font1, Jose Pierre Otazu-Moudelle1, Inés Pérez Sancristóbal1 and lydia Abasolo2, 1Hospital Clinico San Carlos, Madrid, Spain, 2Hospital Clínico San Carlos, Madrid, Spain

    Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone an enormous change in the last two decades with the use of biological Disease Modifying Drugs…
  • Abstract Number: 0743 • ACR Convergence 2023

    Risk and Temporal Trends of Heart Failure Subtypes in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study

    Tate Johnson1, Yangyuna Yang1, Punyasha Roul1, Joshua Baker2, Brian Sauer3, Grant Cannon4, Ted R Mikuls5 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3Salt Lake City VA/University of Utah, Salt Lake City, UT, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: There has been limited study of the risk of heart failure (HF) subtypes in RA at a population level, given the requirement for left…
  • Abstract Number: 0805 • ACR Convergence 2023

    De-escalation of Anti-TNFs in Older Adults with Rheumatoid Arthritis

    Jiha Lee1, Navasuja Kumar1, Mohammed Kabeto1, Andrzej Galecki1, Chiang-Hua Chang1, Namrata Singh2, Raymond Yung3, Una Makris4 and Julie Bynum1, 1University of Michigan, Ann Arbor, MI, 2University of Washington, Bellevue, WA, 3Michigan Medicine, Ann Arbor, MI, 4UT Southwestern Medical Center and Dallas VA, Dallas, TX

    Background/Purpose: Biologic disease modifying anti-rheumatic drugs (bDMARDs) such as anti-tumor necrosis factors(anti-TNFs) improve clinical and radiographic outcomes in rheumatoid arthritis (RA). However, their use is…
  • Abstract Number: 0973 • ACR Convergence 2023

    Real-World Comparative Effectiveness Study of Janus Kinase Inhibitors Compared to Biologic Disease Modifying Antirheumatic Drugs in Korean Patients with Rheumatoid Arthritis

    Soo-Kyung Cho1, Yeo-Jin Song1, Jungyong Han2, Hye Won Kim3, Eunwoo Nam3, Sang Won Lee4, Shin-Seok Lee5, Hye-Soon Lee6, Sung-Hoon Park7, Yeon-Ah Lee8, Sung Hae Chang9, Min-Chan Park10, Hyoun-Ah Kim11, Hyun-Sook Kim12, Bo Young Yoon13, Yong-Gil Kim14, Hae-Rim Kim15, Jae Hoon Kim16, Jisoo Lee17, Jeongim Choi18, Wan-Sik Uhm19 and Yoon-Kyoung Sung1, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 3Hanyang University Institute for Rheumatology Research, Seoul, South Korea, 4Hanyang University, Seoul, South Korea, 5Chonnam National University Medical School & Hospital, Gwangju, South Korea, 6Hanyang University, Guri, South Korea, 7Daegu Catholic University School of Medicine, Daegu, South Korea, 8Kyung Hee University Hospital, Seoul, South Korea, 9Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, 10Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, 11Ajou University School of Medicine, Suwon, South Korea, 12Soonchunhyang University Seoul Hospital, Seoul, South Korea, 13Inje University Ilsan Paik Hospital, Goyang, South Korea, 14Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, 15Rheumatology, Konkuk University Medical Center, Seoul, South Korea, 16Korea University Medical Center, Seoul, South Korea, 17Ewha Womans Univ College of Medicine, Seoul, South Korea, 18Busan Saint Mary's Hospital, Busan, South Korea, 19Uhm's Rheumatism Clinic, Seoul, South Korea

    Background/Purpose: Although clinical trials have shown similar effectiveness between Janus kinase inhibitors (JAKi) and biologic disease-modifying anti-rheumatic drugs (bDMARDs), the choice between these two options…
  • Abstract Number: 1015 • ACR Convergence 2023

    Health Care Access in an Indigenous North American Population of Rheumatoid Arthritis Patients and Their At-risk First-Degree Relatives

    Dana Wiens1, David Robinson1, Irene Smolik1, Cheryl Barnabe2, Hani El-Gabalawy1 and Liam O'Neil1, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Calgary, Calgary, AB, Canada

    Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease that requires access to subspecialty care. Although Canada has a universal healthcare system, there are complex…
  • Abstract Number: 1257 • ACR Convergence 2023

    The Psychological Experience of Work for People with Inflammatory Arthritis (IA)

    Joan Westreich1, Adena Batterman1, Anna Balakrishnan1, Roberta Horton1, Minerva Nong1, Vivian Bykerk2 and Theodore Fields1, 1Hospital for Special Surgery, New York, NY, 2Department of Rheumatology, Hospital for Special Surgery, New York, NY

    Background/Purpose: A large body of research reports that people with inflammatory arthritis (IA) are at increased risk for work disability, which profoundly affects all aspects…
  • Abstract Number: 1276 • ACR Convergence 2023

    Multimorbidity Burden Predicts Lower Likelihood of Remission in Patients with Rheumatoid Arthritis

    Cynthia Crowson, Chanakya Kodishala, Tina Gunderson, Atkinson Elizabeth, Vanessa Kronzer, John Davis, Courtney Arment, Delamo Bekele, Thomas Mason, Lynne Peterson, Kerry Wright and Elena Myasoedova, Mayo Clinic, Rochester, MN

    Background/Purpose: Seropositivity has historically been associated with poor disease outcomes in patients with rheumatoid arthritis (RA). Seronegative RA is on the rise and is associated…
  • Abstract Number: 1292 • ACR Convergence 2023

    Active Rheumatoid Arthritis Patients Exhibit an Altered Serum Lipidomic Profile Directly Linked to Disease Activity, Which Is Reversed by Biologic and Targeted Synthetic DMARD

    Chary Lopez-Pedrera1, Laura Muñoz-Barrera2, Beatriz Vellón2, Rocio Guzman2, Tomás Cerdó2, Rafaela Ortega Castro3, Jerusalem Calvo4, Mª Angeles Aguirre5, Pedro Segui2, Ivan Arias de la Rosa6, Maria del Carmen Abalos-Aguilera7, Desiree Ruiz-Vilchez2, Christian Merlo-Ruiz2, Jose Javier Perez-Venegas8, Javier Godoy9, Dolores Ruiz-Montesinos10, Carmen Dominguez8, Carlos Rodriguez-Escalera11, Carmen Romero-Barco12, Antonio Fernandez-Nebro12, Natalia Mena Vazquez13, Julia Uceda Montañez14, Charo Santos14, Nuria Barbarroja15, Eduardo Collantes Estévez16, Mª del Mar Malagon2, Alejandro Escudero Contreras4 and Carlos Perez-Sanchez17, 1IMIBIC - Reina Sofia Hospital, Córdoba, Spain, 2IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 3Hospital Reina Sofía, Cordoba, Spain, 4Reina Sofia University Hospital, Córdoba, Spain, 5Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, 6IMIBIC/Reina Sofia Hospital/University of Cordoba. Rheumatology service. Cordoba. Spain, Cordoba, Spain, 7Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, 8Virgen Macarena University Hospital, Sevilla, Spain, 9Jaen University Hospital, Jaen, Spain, 10Hospital Universitario Virgen Macarena, Sevilla, Spain, 11Virgen de la Victoria Hospital, Malaga, Spain, 12Hospital Regional Universitario de Málaga, Malaga, Spain, 13IBIMA, Málaga, Spain, 14Hospital Virgen de Valme, Sevilla, Spain, 15University of Cordoba, Córdoba, Spain, 16Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, 17IMIBIC, Córdoba, Spain

    Background/Purpose: Lipid metabolism impacts immune cell plasticity, activation, differentiation, and function, making the analysis of the lipidomic profile crucial in understanding chronic inflammatory diseases like…
  • « Previous Page
  • 1
  • …
  • 72
  • 73
  • 74
  • 75
  • 76
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology